Literature DB >> 29790086

Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

S Giannattasio1, F Megiorni2, V Di Nisio3, A Del Fattore4, R Fontanella5, S Camero2, C Antinozzi1, C Festuccia6, G L Gravina6, S Cecconi3, C Dominici2, L Di Luigi1, C Ciccarelli6, P De Cesaris6, A Riccioli5, B M Zani6, A Lenzi7, R G Pestell8, A Filippini5, C Crescioli1, V Tombolini9, F Marampon10,11.   

Abstract

PURPOSE: Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in childhood, rarely affects adults, preferring male. RMS expresses the receptor for androgen (AR) and responds to androgen; however, the molecular action of androgens on RMS is unknown.
METHODS: Herein, testosterone (T) effects were tested in embryonal (ERMS) and alveolar (ARMS) RMS cell lines, by performing luciferase reporter assay, RT-PCR, and western blotting experiments. RNA interference experiments or bicalutamide treatment was performed to assess the specific role of AR. Radiation treatment was delivered to characterise the effects of T treatment on RMS intrinsic radioresistance.
RESULTS: Our study showed that RMS cells respond to sub-physiological levels of T stimulation, finally promoting AR-dependent genomic and non-genomic effects, such as the transcriptional regulation of several oncogenes, the phosphorylation-mediated post-transductional modifications of AR and the activation of ERK, p38 and AKT signal transduction pathway mediators that, by physically complexing or not with AR, participate in regulating its transcriptional activity and the expression of T-targeted genes. T chronic daily treatment, performed as for the hormone circadian rhythm, did not significantly affect RMS cell growth, but improved RMS clonogenic and radioresistant potential and increased AR mRNA both in ERMS and ARMS. AR protein accumulation was evident in ERMS, this further developing an intrinsic T-independent AR activity.
CONCLUSIONS: Our results suggest that androgens sustain and improve RMS transformed and radioresistant phenotype, and therefore, their therapeutic application should be avoided in RMS post puberal patients.

Entities:  

Keywords:  Androgen receptor; Radioresistance; Rhabdomyosarcoma; Signal transduction; Testosterone

Mesh:

Substances:

Year:  2018        PMID: 29790086     DOI: 10.1007/s40618-018-0900-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

1.  Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.

Authors:  Sophie Lehn; Nicholas P Tobin; Pontus Berglund; Kristina Nilsson; Andrew H Sims; Karin Jirström; Pirkko Härkönen; Rebecca Lamb; Göran Landberg
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.

Authors:  M Fu; C Wang; A T Reutens; J Wang; R H Angeletti; L Siconolfi-Baez; V Ogryzko; M L Avantaggiati; R G Pestell
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance.

Authors:  Mette Brandt Eriksen; Dorte Glintborg; Michael Friberg Bruun Nielsen; Marianne Antonius Jakobsen; Klaus Brusgaard; Qihua Tan; Michael Gaster
Journal:  Biochem Biophys Res Commun       Date:  2014-08-14       Impact factor: 3.575

4.  Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.

Authors:  Maofu Fu; Chenguang Wang; Jian Wang; Xueping Zhang; Toshiyuki Sakamaki; Y G Yeung; Chawnshang Chang; Torsten Hopp; Suzanne A W Fuqua; Ellis Jaffray; Ron T Hay; Jorma J Palvimo; Olli A Jänne; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 5.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

6.  Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.

Authors:  Ryo Fukuda; Kiichi Hirota; Fan Fan; Young Do Jung; Lee M Ellis; Gregg L Semenza
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

7.  PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.

Authors:  Giovanni Luca Gravina; Francesco Marampon; Paola Muzi; Andrea Mancini; Margherita Piccolella; Paola Negri-Cesi; Marcella Motta; Andrea Lenzi; Ernesto Di Cesare; Vincenzo Tombolini; Emmanuele A Jannini; Claudio Festuccia
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

8.  p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.

Authors:  Carmela Ciccarelli; Francesco Marampon; Arianna Scoglio; Annunziata Mauro; Cristina Giacinti; Paola De Cesaris; Bianca M Zani
Journal:  Mol Cancer       Date:  2005-12-13       Impact factor: 27.401

9.  Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.

Authors:  Francesco Marampon; Carmela Ciccarelli; Bianca M Zani
Journal:  Mol Cancer       Date:  2006-08-09       Impact factor: 27.401

Review 10.  Radiation-induced signaling pathways that promote cancer cell survival (review).

Authors:  Ashley L Hein; Michel M Ouellette; Ying Yan
Journal:  Int J Oncol       Date:  2014-08-20       Impact factor: 5.650

View more
  3 in total

1.  NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Authors:  Francesco Marampon; Silvia Codenotti; Francesca Megiorni; Andrea Del Fattore; Simona Camero; Giovanni Luca Gravina; Claudio Festuccia; Daniela Musio; Francesca De Felice; Valerio Nardone; Anna Natalizia Santoro; Carlo Dominici; Alessandro Fanzani; Luigi Pirtoli; Antonella Fioravanti; Vincenzo Tombolini; Sara Cheleschi; Paolo Tini
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-30       Impact factor: 4.553

2.  Phosphodiesterase Type-5 Inhibitor Tadalafil Modulates Steroid Hormones Signaling in a Prostate Cancer Cell Line.

Authors:  Viviana M Bimonte; Francesco Marampon; Ambra Antonioni; Simona Fittipaldi; Elisabetta Ferretti; Richard G Pestell; Mariaignazia Curreli; Andrea Lenzi; Giovanni Vitale; Antonio Brunetti; Silvia Migliaccio; Antonio Aversa
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

Review 3.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.